Intelligent Bio Solutions Inc. (INBS)
NASDAQ:INBS
INBS Stock Chart & Stats
$1.03
-$0.03(-2.02%)
At close: 4:00 PM EST
$1.03
-$0.03(-2.02%)
Day’s Range― - ―
52-Week Range$2.42 - $24.90
Previous CloseN/A
Volume32.28K
Average Volume (3M)77.36K
Market Cap
$4.92M
Enterprise Value$4.51M
Total Cash (Recent Filing)$740.37K
Total Debt (Recent Filing)$3.45M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding2,001,173
10 Day Avg. Volume141,402
30 Day Avg. Volume77,358
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit4.21
Enterprise Value/Ebitda-0.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale And Cost SavingsA strategic manufacturing partnership that quadruples capacity and targets >40% production cost savings plus ~20ppt gross margin uplift is a durable structural improvement. It lowers unit costs, supports scalable fulfillment for larger contracts, and materially improves long-term margin potential as volumes grow.
Pursuing FDA 510(k) U.S. ClearanceRunning a 510(k) clinical program to move the product beyond 'Forensic Use Only' is a structural business catalyst. U.S. clearance would materially expand addressable market, enable broader commercial channels, and create persistent revenue opportunities across workplace, clinical, and law-enforcement segments.
Improving Revenue And Solid Product MarginsSustained revenue growth combined with ~46% gross margin indicates attractive unit economics at the product level. If maintained, these fundamentals provide a realistic path to operating leverage once fixed-cost absorption improves, supporting longer-term profitability prospects.
Bears Say
Persistent Cash BurnSignificant negative operating and free cash flow is a lasting constraint: continued burn forces dependence on external financing, limits discretionary investment, and raises execution risk. Absent sustained margin expansion or revenue acceleration, funding needs will persist over the coming months.
Ongoing Equity Financing And Dilution RiskThe company’s active use of equity awards and an ATM program signals structural reliance on share issuance to fund operations. This creates persistent dilution risk and can compress per-share economics until the business becomes cash-flow positive and less dependent on capital markets.
Losses Far Exceed Revenue BaseNet margins near -315% reflect a cost structure that dramatically outpaces current revenues. Without durable cost reduction or much higher sales volume, losses are likely to persist, constraining return metrics and making the path to self-funding and sustainable profits challenging.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions Inc.’s price range in the past 12 months?
Intelligent Bio Solutions Inc. lowest stock price was $2.42 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions Inc.’s market cap?
Intelligent Bio Solutions Inc.’s market cap is $4.92M.
When is Intelligent Bio Solutions Inc.’s upcoming earnings report date?
Intelligent Bio Solutions Inc.’s upcoming earnings report date is May 13, 2026 which is in 27 days.
How were Intelligent Bio Solutions Inc.’s earnings last quarter?
Intelligent Bio Solutions Inc. released its earnings results on Feb 12, 2026. The company reported -$2.82 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.82.
Is Intelligent Bio Solutions Inc. overvalued?
According to Wall Street analysts Intelligent Bio Solutions Inc.’s price is currently Overvalued.
Does Intelligent Bio Solutions Inc. pay dividends?
Intelligent Bio Solutions Inc. does not currently pay dividends.
What is Intelligent Bio Solutions Inc.’s EPS estimate?
Intelligent Bio Solutions Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intelligent Bio Solutions Inc. have?
Intelligent Bio Solutions Inc. has 2,001,173 shares outstanding.
What happened to Intelligent Bio Solutions Inc.’s price movement after its last earnings report?
Intelligent Bio Solutions Inc. reported an EPS of -$2.82 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions Inc.?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
― Insiders
0.36% Mutual Funds
0.01% Other Institutional Investors
99.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---